Introduction
Low coverage whole genome sequencing (lcWGS) 145 Genomic libraries were constructed from 10 ng cfDNA with the NEBNext Ultra 146 II kit and sequenced with 100bp single-end reads on HiSeq2500 in rapid mode 147 (0.42x median coverage). Data was aligned (hg19 reference genome) with Bowtie 148 (v0.12.9), and processed as described [20] . logRatios were normalised against a Figure 2C ). 25 fraction of on-target reads is usually low when using small targeted sequencing 175 panels and low input DNA, so we first assessed how the on-target fraction could be preparations were started in parallel from each of four cfDNA samples, using the 1.5 178 h fast-hybridization protocol. Then, post-capture washes were performed at 65°C in 179 one library and at 70°C in the other. Sequencing generated similar read numbers 180 (65°C: 92,820,887; 70°C: 102,582,694 median reads/sample) and the on-target 181 fraction significantly (p=0.0011) increased from 30-35% to 71-74% with the 70°C 182 protocol ( Figure 1A) . Hence, the more stringent conditions were chosen for our 183 standard protocol. Target exon coverage was even with this solution hybrid-capture 184 technique and was not subject to the gaps commonly seen with commercial 185 amplicon sequencing designs (online Supplemental Figure 3 ). This would be 186 particularly advantageous for the analysis of tumor suppressor genes where driver 187 mutations often spread across large parts of the gene. 188 We next used MBCs to de-duplicate sequencing data and perform error Figure 4 ), which was within the optimal 195 range for barcode error correction [21] . After MBC de-duplication, the median on-196 target depth with the 70 o C protocol was 1,782x. This was theoretically sufficient to 197 achieve a detection limit as low as 1 mutated DNA fragment in 1,782 molecules 198 (0.056%). However, the analytical sensitivity for de novo mutation detection is lower 199 in practice since more than one read is required to support robust bioinformatics 200 calling. Thus, we designed a mixing experiment to test the ability to detect and 201 bioinformatically call mutations with low VAFs. mapping to the same genomic position but differing in whether the variant was seen 228 in read 1 or read 2 in paired-end sequencing ( Figure 1D ). These were highly likely to 229 represent the forward and reverse strand of the double-stranded input cfDNA 230 molecule as observed previously [15] . Based on this observation, we developed the 231 duplexCaller bioinformatics tool that identified variants supported by duplex reads 232 (online Supplemental Methods file) and added the requirement for such a 'duplex-233 configuration' to be present to accept a mutation as genuine. The presence of a 234 variant in at least one additional family with a different alignment position was also 235 added to the post-call filters to assure high specificity. Thus, a variant had to be 236 present in ≥3 consensus DNA families in order to be accepted as a mutation call in 237 the MBC de-duplicated data. For a meaningful comparison, mutations in the 238 standard de-duplicated data were also required to be present in ≥3 reads. 239 We then compared SureCall calls for the mixing experiment on standard-240 versus MBC-deduplicated data and quantified how many of the homozygous SNPs 241 from sample A that were present at 0.15% in the cfDNA mixture were called. were called with only 2 likely false positive variants. We assessed why calling with 254 MBC error correction failed to identify the 5 other SNPs. Each of these had VAFs 255 <0.1% when visualized in IGV [23] , which was below the minimum VAF of 0.1% that 256 can be called by SureCall. We also assessed the number of false positive calls in 257 standard de-duplicated data at the maximum VCQT that identified the same four true SNPs but no mutations with lower frequency (online Supplemental Table 3 ), further 263 supporting the high analytical specificity of this MBC technology. 265 cfDNA from 28 patients with mCRC were consecutively analyzed. Seven were 266 sequenced with the 65°C protocol and 21 with the 70°C protocol. The median 267 sequencing depth was higher with 70°C (2,087x) than 65°C (1,205x) ( Figure 2A ). 268 We then analyzed the concordance and discordance of mutation calls within 269 the target regions common to the tumor biopsy sequencing assay and our cfDNA- Supplemental Table 4 ) and four biopsies had been subjected to routine 272 clinical amplicon sequencing of 5 genes (BRAF, KRAS, NRAS, PIK3CA and TP53). 273 One case had failed tissue sequencing.
264

Concordance of cfDNA-and tumor-sequencing in mCRC patients
274
88% (80/91) of all mutations that had been found by tumor sequencing were 275 called in the cfDNA (Figure 2A ). All 11 mutations not called in cfDNA were from only 3 cases. Inspection of the sequencing data on IGV revealed that 5/11 mutations 277 were present in cfDNA at VAFs below the SureCall detection limit ( Figure 2B ).
278
Sufficient cfDNA remained from case 8 for orthogonal analysis by ddPCR. Using 279 manufacturer-validated ddPCR-probes for the BRAF V600E mutation we identified 280 2,830 wild type DNA fragments but no mutated fragments (data not shown). This 281 confirmed that the absence of sufficiently abundant tumor-derived cfDNA molecules, 282 rather than technical failure, explained the inability to detect mutations. 283 We next assessed mutations called by cfDNA-Seq in genes that had not been 284 sequenced in corresponding tumor tissue. APC mutations were detected in each of 4 285 cases whose tumors had only been analyzed with the 5-gene amplicon panel ( Figure   286 2A). Furthermore, one mutation was found in each of FBXW7, CTNNB1, TCF7L2, 287 ATM and SMAD4. We also detected mutations in APC, TP53 and KRAS in case 28 288 that had failed prior tumor tissue sequencing attempts. In total, 11 of these 13 289 mutations (85%) encoded protein changes previously reported in the COSMIC 290 cancer mutation database [24] and all variants in the tumour suppressor genes APC 291 and FBXW7 were truncating and hence likely driver mutations. This demonstrated 292 that our assay could detect biologically and clinically important cancer mutations 293 directly from cfDNA. 294 We then investigated mutations that had been called in cfDNA but were 295 absent when the same gene had been analyzed in tumor tissue: 7 in TP53, 7 in 296 ATM, 3 in PIK3CA, 2 in SMAD4 and one each in KRAS, FBXW7 and TCF7L2. All with a 5-gene assay using amplicons (87.2%) [1] and a 54-gene assay using target-385 capture (85%) [14, 30] . Furthermore, indels are more difficult to call than point be molecularly profiled due to unobtainable or inadequate biopsy tissues [16, 31] .
411
In conclusion, this cfDNA-Seq approach with customizable and off-the-shelf 412 reagents showed a similar performance to published techniques that use bespoke 413 reagents and more complex analyses. occurs in all reads then the consensus read sequence will be variant for that base (top). However if a variant (green) is only detected in a small fraction of the reads in the family, it will be disregarded and the consensus read sequence will be wild-type 
